MGMT and glioblastoma: We then analyzed the clinical data of 66 patients with GBM and found that there was no correlation between EGFRvIII expression and age, sex, IDH1 mutation, 1p/19q codeletion, MGMT promoter methylation, radiotherapy, or chemotherapy in GBM patients (p > 0.05) (Table 1).